Evidence map›Paper›PMID 41624407›Full record

ArticleMolecular therapy. Oncology2026

Co-editing of NKG2A and FAS increases long-term cytotoxic capacity and persistence of CAR NK cells.

Juliane Mietz, Lukas Egli, Meike Misiune, Arianna Picozzi, Nicolò Coianiz, Danielle Thompson, Marianna Ponzo, Alisson Charmey, Beat Bornhauser, Chiara F Magnani and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Juliane MietzCellular Immunotherapy, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Lukas EgliCellular Immunotherapy, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Meike MisiuneCellular Immunotherapy, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Arianna PicozziCellular Immunotherapy, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Nicolò CoianizCellular Immunotherapy, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Danielle ThompsonViral Immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Marianna PonzoDepartment of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.
Alisson CharmeyDepartment of Oncology, University Children's Hospital Zurich, Zurich, Switzerland.
Beat BornhauserDepartment of Oncology, University Children's Hospital Zurich, Zurich, Switzerland.
Chiara F MagnaniDepartment of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.
Christian MünzViral Immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Obinna ChijiokeCellular Immunotherapy, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK) cells have the intrinsic ability to kill cancer cells and are thus targeted in immunotherapy. Anti-CD19 CAR NK cells have shown efficacy in clinical studies in treating B cell malignancies; however, the full cytotoxic capacities of CAR NK cells may be limited by the expression of inhibitory receptors on NK cells. The NKG2A/HLA-E axis has been identified as an important negative regulator of NK cell activity, and different strategies on genome and protein levels are evaluated to block NKG2A-mediated inhibition. In this study, we engineered CD19 CAR NK cells harboring genetic disruption of

Indexed as

antigen-loss resistanceB cell malignanciescancer immunotherapyCAR NK cellsCRISPR-Cas9FAS co-editingMT: Regular IssueNKG2A editingsite-specific CAR knockin

Identifiers

PMID41624407
PMCPMC12859412

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.